Navigation Links
Proteolix's Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
Date:4/2/2008

SOUTH SAN FRANCISCO, Calif., April 2, 2008 /PRNewswire/ -- Proteolix, Inc., a clinical-stage company engaged in the development of novel pharmaceutical therapies for the treatment of cancer and immunological conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to carfilzomib, a selective blocker of proteasome activity for the treatment of multiple myeloma. The orphan drug designation encompasses all subsets of multiple myeloma and Waldenstrom's macroglobulinemia.

"I am very pleased by our receipt of this designation for carfilzomib," said Susan Molineaux, Ph.D., the Company's President and CEO. "To date we have been encouraged by carfilzomib's early-stage clinical results in multiple myeloma, and we continue to believe it has the potential to offer cancer patients a new and effective treatment for their disease."

The Orphan Drug Act of 1983 allows the FDA to grant orphan drug status to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. According to the SEER Database of the National Cancer Institute (2004), the U.S. prevalence of multiple myeloma was 53,712 patients. The Orphan Drug Act provides the drug developer with several financial benefits and incentives related to the orphan drug, including tax credits for clinical research costs, ability to apply for annual grant funding, clinical research trial design assistance, waiver of Prescription Drug User Fee Act (PDUFA) filing fees, and a seven-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified indication.

About Multiple Myeloma

Multiple myeloma is cancer of the plasma cell. It begins in the bone marrow, where blood cells are made. The plasma cell is a type of white blood cell that fights infections by making antibodies. Cancerous plasma cells, also called myeloma cells, divide and grow out of control, build
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
3. Pharmasset Receives $10 Million of Working Capital
4. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
5. Actavis Receives Approval of Generic Wellbutrin SR(R) and Zyban(R) Tablets in the U.S.
6. Seneca Valley High School Student Receives Science Award From MedImmune
7. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
8. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
9. Oregon Health Care Quality Corporation Receives Important Designation from U.S. Department of Health and Human Services
10. AdvanDx Receives Frost & Sullivans Rapid In-Vitro Diagnostic Technology Innovation of the Year Award
11. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...swire/ -- Biotech firm Replikins Ltd., which has a... pandemic through the prediction, outbreak, and pr...its latest biochemical analysis of the virus. The ...ine Flu") virus has dropped from its peak of 3.7 (...he spring of 2009 to resting non-epidemic levels t...
(Date:11/25/2009)...wire/ - Cytochroma today announced the appointment.... Moldt will replace Mr. Ulrik Spork as the Novo A...er of Board members remains unchanged at six membe...ldt to the board and look forward to benefiting fr...nues to make progress in becoming a leading CKD-fo...
(Date:11/25/2009)...ire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq:...m.D., president and chief executive officer, will ...re Conference. , ,Presentation details are as fol...rence,Date: Tuesday, December 1, 2009,Time: ... Palace Hotel, New York, NY,Webcast: <a href=,h...
(Date:11/24/2009)...also Visit Detroit , (Voc...ench Ambassador for International Investment, and ... , , ,What: Ambassador Appia is available to meet...ives adopted by France to further develop the fina...n and development., , ,When: Available for Intervi...
Breaking Biology Technology:Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Cytochroma Announces Appointment of Peter Moldt to Board of Directors 2Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...Soliris(R) Sales Reflect Strong 2007 Launch; Posit... U.S. and International Markets, Fourth Quarter...ulizumab) net product sales were $33.9 million in ... million in Q3 2007., * Q4 GAAP net loss was $12....AP net loss of $20.1 million, or $0.55 per share, ...
...Three-Year Extension for Integrated Drug Discovery...s for the Treatment of Huntington Disease, HAMBUR...ornia, February,14 Evotec AG (Frankfurt Stock Exc...Inc., a not-for-profit organization,pursuing a bio...Disease,(HD), has extended its collaboration with ...
..., Nanotechnology researchers are developing the p...able to generate electricity to power small electr... others whose physical motion could be harnessed a... 14 issue of the journal Nature details how pairs ...s can generate electrical current using the piezoe...
Other Biology Technology:Alexion Reports Fourth Quarter and Full Year 2007 Results 2Alexion Reports Fourth Quarter and Full Year 2007 Results 3Alexion Reports Fourth Quarter and Full Year 2007 Results 4Alexion Reports Fourth Quarter and Full Year 2007 Results 5Alexion Reports Fourth Quarter and Full Year 2007 Results 6Alexion Reports Fourth Quarter and Full Year 2007 Results 7Alexion Reports Fourth Quarter and Full Year 2007 Results 8Alexion Reports Fourth Quarter and Full Year 2007 Results 9Alexion Reports Fourth Quarter and Full Year 2007 Results 10Alexion Reports Fourth Quarter and Full Year 2007 Results 11Alexion Reports Fourth Quarter and Full Year 2007 Results 12Alexion Reports Fourth Quarter and Full Year 2007 Results 13Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million 2Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million 3Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million 4Fiber-based nanotechnology in clothing could harvest energy from physical movement 2Fiber-based nanotechnology in clothing could harvest energy from physical movement 3Fiber-based nanotechnology in clothing could harvest energy from physical movement 4
(Date:11/30/2009)...of lower early bird registration rates and registe...s of 2010 at http://www.iofwco-ecceo10.org/ , ...International Osteoporosis Foundation (IOF) and th...ts of Osteoporosis and Osteoarthritis (ESCEO). Mor...e expected to attend. The exciting scientific prog...
(Date:11/30/2009)...lorless and odorless radioactive gas that is produ...a product of uranium decay and is found in trace a...roundwater as well as building materials, plants, ...ion is expressed as the amount of radiation that w... a liter of air; thus the units are picocuries per...
(Date:11/26/2009).... (November 26, 2009) Whitehead researchers have ...ells to pinpoint specific genes and proteins used ... . , In most human cell cultures genes are prese...d one from the mother. Gene inactivation by mutati...is inactivated, the second copy usually remains ac...
Breaking Biology News(10 mins):Health Physics Society recommends considering action for indoor radon below current guidelines 2Knockouts in human cells point to pathogenic targets 2U S Court of Appeals Upholds AstraZeneca AWP Settlement 6446 1U S Court of Appeals Upholds AstraZeneca AWP Settlement 6446 2U S Court of Appeals Upholds AstraZeneca AWP Settlement 6446 3Spanish biotechnology should focus on food and plant sectors to be more competitive 14936 1Spanish biotechnology should focus on food and plant sectors to be more competitive 14936 2H1N1 Pandemic May Have Peaked in October in U S According to Quest Diagnostics 61864 1H1N1 Pandemic May Have Peaked in October in U S According to Quest Diagnostics 61864 2H1N1 Pandemic May Have Peaked in October in U S According to Quest Diagnostics 61864 3
... capable of metacognition—that is, they can posses...ility, which can also be thought of as the capacit...es, was previously only recognized in humans and o...n Foote and Jonathon Crystal of the University of ...iology, published by Cell Press, on March 8th. , A...
...n ovarian cancer may present a new target for diag...ccording to researchers at the University of Illin...f Pharmacy found that interfering with the product...d invasiveness of tumor cells in test-tube experim...human ovarian tumors overexpressed polypyrimidine ...
...om the lungs of transplant patients demonstrates f...de in adult organs and are not derived from bone m...ls may be able to help with the rejection of donat... , The study by University of Michigan Health Syst... number of lung transplant patients who experience...
Other Biology News:Metacognition: Faced with a test, rats can check their knowledge first 2RNA splicing factor implicated in ovarian tumor cell growth 2Type of stem cell found to reside in transplanted lungs 2Type of stem cell found to reside in transplanted lungs 3
Anti-Yersinia pestis Monoclonal Antibody, Unconjugated from ViroStat Inc.
Rabbit Anti-Olfactory Receptor LS189744 Polyclonal Antibody, Unconjugated from Abcam
Anti-Varicella-zoster Virus, Nucleocapsid Protein Monoclonal Antibody, Unconjugated from CHEMICON
Mouse Anti-Zeralenone Monoclonal Antibody, Unconjugated, Clone 11C9 from Abcam
Biology Products: